Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

The Role of Integrin alpha1beta1 in a Murine Model of Post-traumatic Osteoarthritis

FY 2013-14

Summary
Osteoarthritis is the most common type of degenerative joint disease affecting 4.4 million Canadians and costing Canadians 10 billion dollars in direct costs alone. If no improvements are seen in the prevention and/or care of osteoarthritis, the prevalence is estimated to more than double to 10.4 million people by 2040. Due to the lack of symptoms in its initial stages, the detection of osteoarthritis often occurs years after joint damage has begun. This makes it difficult to implement early intervention that might prevent or slow down the progression of the disease. Injury-induced osteoarthritis accounts for approximately 12% of all incidences of osteoarthritis, and this proportion is expected to increase given the rise in participation and injury prevalence in youth sports. In just 12 years (1999-2010), there has been a 400% increase in pediatric knee injuries, and approximately 50% of these individuals develop osteoarthritis associated pain within 10 to 20 years of injury. Despite these disturbing statistics, the clearly defined initiation of osteoarthritis disease at the time of injury enables these high risk individuals to be identified and may allow for early intervention before any signs of osteoarthritis arise. This proposal investigates integrin alpha1beta1, a collagen receptor expressed by cartilage cells, and its potential as a pharmaceutical target for delaying the development of injury-induced osteoarthritis. Interestingly, cartilage cells overexpress integrin alpha1beta1 during the early stages of osteoarthritis and the presence of integrin alpha1beta1 delays spontaneous osteoarthritis by 2 months in mice (equivalent to 7 years in humans). The role of integrin alpha1beta1 in injury induced osteoarthritis and the mechanism by which it delays osteoarthritis remains to be discovered. Recently, integrin alpha1beta1 has been shown to dampen epidermal growth factor receptor, a receptor known to accelerate the progression of osteoarthritis when allowed to function unhindered. In this proposal we hypothesize that integrin alpha1beta1 slows the progression of injury induced osteoarthritis in mice and that this occurs due to its dampening effects on epidermal growth factor receptor. The aim of this study is to evaluate the role of integrin alpha1beta1 in injury induced osteoarthritis using genetically mutated mice that lack integrin alpha1beta1, and to assess whether the mechanism by which it protects involves epidermal growth factor receptor. In this study, osteoarthritis will be induced by performing a surgery to destabilize one of the menisci in the mouse knee. This will be performed in normal and integrin alpha1beta1 mutated mice. One additional group of mice will be treated with the drug erlotinib, which dampens the action of epidermal growth factor receptor. At 2, 4, 8, and 12 weeks post-surgery, osteoarthritis severity will be measured by measuring the structure and size of the soft and bony tissues of the knee. In addition, mouse activity levels will be measured, including sleeping, climbing, and eating. Through this study, we will be able to determine the influence of integrin alpha1beta1 on the progression of injury induced osteoarthritis and clarify whether epidermal growth factor receptor is involved in its mechanism. Consequently, this study will provide insight into the potential of integrin alpha1beta1 as a pharmaceutical target to treat injury induced osteoarthritis immediately after injury, and thus slow down the progression of this disease and lessen the economic burden brought on by the increasing prevalence of osteoarthritis in Canada.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
312051
Name
Shin SungYong
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Integrin alpha1beta1 in a Murine Model of Post-traumatic Osteoarthritis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cartilage; Destabilization Of Medial Meniscus; Epidermal Growth Factor Receptor; Erlotinib; Histology; Integrin A1í1; Microct; Mouse; Post-Traumatic Osteoarthritis
Abstract
Osteoarthritis is the most common type of degenerative joint disease affecting 4.4 million Canadians and costing Canadians 10 billion dollars in direct costs alone. If no improvements are seen in the prevention and/or care of osteoarthritis, the prevalence is estimated to more than double to 10.4 million people by 2040. Due to the lack of symptoms in its initial stages, the detection of osteoarthritis often occurs years after joint damage has begun. This makes it difficult to implement early intervention that might prevent or slow down the progression of the disease. Injury-induced osteoarthritis accounts for approximately 12% of all incidences of osteoarthritis, and this proportion is expected to increase given the rise in participation and injury prevalence in youth sports. In just 12 years (1999-2010), there has been a 400% increase in pediatric knee injuries, and approximately 50% of these individuals develop osteoarthritis associated pain within 10 to 20 years of injury. Despite these disturbing statistics, the clearly defined initiation of osteoarthritis disease at the time of injury enables these high risk individuals to be identified and may allow for early intervention before any signs of osteoarthritis arise. This proposal investigates integrin alpha1beta1, a collagen receptor expressed by cartilage cells, and its potential as a pharmaceutical target for delaying the development of injury-induced osteoarthritis. Interestingly, cartilage cells overexpress integrin alpha1beta1 during the early stages of osteoarthritis and the presence of integrin alpha1beta1 delays spontaneous osteoarthritis by 2 months in mice (equivalent to 7 years in humans). The role of integrin alpha1beta1 in injury induced osteoarthritis and the mechanism by which it delays osteoarthritis remains to be discovered. Recently, integrin alpha1beta1 has been shown to dampen epidermal growth factor receptor, a receptor known to accelerate the progression of osteoarthritis when allowed to function unhindered. In this proposal we hypothesize that integrin alpha1beta1 slows the progression of injury induced osteoarthritis in mice and that this occurs due to its dampening effects on epidermal growth factor receptor. The aim of this study is to evaluate the role of integrin alpha1beta1 in injury induced osteoarthritis using genetically mutated mice that lack integrin alpha1beta1, and to assess whether the mechanism by which it protects involves epidermal growth factor receptor. In this study, osteoarthritis will be induced by performing a surgery to destabilize one of the menisci in the mouse knee. This will be performed in normal and integrin alpha1beta1 mutated mice. One additional group of mice will be treated with the drug erlotinib, which dampens the action of epidermal growth factor receptor. At 2, 4, 8, and 12 weeks post-surgery, osteoarthritis severity will be measured by measuring the structure and size of the soft and bony tissues of the knee. In addition, mouse activity levels will be measured, including sleeping, climbing, and eating. Through this study, we will be able to determine the influence of integrin alpha1beta1 on the progression of injury induced osteoarthritis and clarify whether epidermal growth factor receptor is involved in its mechanism. Consequently, this study will provide insight into the potential of integrin alpha1beta1 as a pharmaceutical target to treat injury induced osteoarthritis immediately after injury, and thus slow down the progression of this disease and lessen the economic burden brought on by the increasing prevalence of osteoarthritis in Canada.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shin, SungYong
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~